A review of recent patents on the protozoan parasite HSP90 as a drug target

Recent Patents on Biotechnology

Volumn 7, Issue 1, 2013, Pages 2-8

  Angel, Sergio O ^a   Matrajt, Mariana ^b   Echeverria, Pablo C ^c  

^a CONICET UNSAM ^*  (Argentina)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

17 AAG; Geldanamycin; HSP90; Patent; Plasmodium; Therapy; Toxoplasma

Indexed keywords

PATENTS AND INVENTIONS; PROTOZOA;

17-AAG; DRUG TARGETS; GELDANAMYCIN; PARASITE-; PATENT; PLASMODIUM; PROTOZOAN PARASITES; THERAPY; TOXOPLASMA; TRYPANOSOMATIDS;

DISEASES;

17 N 3 [2 [2 (3 AMINOPROPOXY)ETHOXY]PROPYL]PENT 4 YNAMIDE 17 DEMETHOXYGELDANAMYCIN; ECHINOCANDIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; RETASPIMYCIN; TANESPIMYCIN; UNCLASSIFIED DRUG;

CANDIDIASIS; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; HUMAN; KINETOPLASTIDA; LIVER TOXICITY; NONHUMAN; PARASITE DEVELOPMENT; PATENT; PLASMODIUM BERGHEI INFECTION; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SURRA; TOXOPLASMA GONDII;

PLASMODIUM FALCIPARUM; PROTOZOA; TOXOPLASMA; TOXOPLASMA GONDII; TRYPANOSOMATIDAE;

ANIMALS; ANTIPROTOZOAL AGENTS; HSP90 HEAT-SHOCK PROTEINS; MOLECULAR TARGETED THERAPY; PATENTS AS TOPIC; PLASMODIUM; PROTOZOAN PROTEINS; TOXOPLASMA;

EID: 84881599012     PISSN: 18722083     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872208311307010002     Document Type: Review

References (52)

1. Monzote L, Siddiq A. Drug development to protozoan diseases. Open Med Chem J 2011; 5: 1-3.
2. WHO. World Malaria Report 2008. Geneva, Switzerland: WHO. 2008. http://www.who.int/malaria/publications/atoz/9789241563697/en/index.html
3. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD. Global malaria mortality between 1980 and 2010: a systematic analysis. The Lancet 2012; 379: 413-431.
4. WHO. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg. 2000; 94:S1-90
5. Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol 2000; 30: 1217-1258.
6. Brynska A, Tomaszewicz-Libudzic E, Wolanczyk T. Obsessivecompulsive disorder and acquired toxoplasmosis in two children. Eur Child Adolesc Psychiatry 2001; 10: 200-204.
7. Miman O, Mutlu EA, Ozcan O, Atambay M, Karlidag R, Unal S. Is there any role of Toxoplasma gondii in the etiology of obsessivecompulsive disorder? Psychiatry Res 2010; 177: 263-265.
8. Yolken RH, Dickerson FB, Fuller Torrey E. Toxoplasma and schizophrenia. Parasite Immunol 2009; 31: 706-715.
9. Vittecoq M, Elguero E, Lafferty KD, Roche B, Brodeur J, Gauthier- Clerc M, Missé D, Thomas F. Brain cancer mortality rates increase with Toxoplasma gondii seroprevalence in France. Infect Genet Evol 2012; 12: 496-498.
10. Thomas F, Lafferty KD, Brodeur J, Elguero E, Gauthier-Clerc M, Missé D. Incidence of adult brain cancers is higher in countries where the protozoan parasite Toxoplasma gondii is common. Biol Lett 2012; 8: 101-103.
11. Rodriguez JB, Szajnman SH. New antibacterials for the treatment of toxoplasmosis; a patent review. Exp Op Rev Pat 2012; 22: 311-333.
12. Palatnik-de-Sousa CB, Day MJ. One Health: the global challenge of epidemic and endemic leishmaniasis. Parasit Vectors 2011; 4: 197.
13. Dias J.C. Elimination of Chagas disease transmission: perspectives. Mem Inst Oswaldo Cruz 2009; 1: 41-45.
14. Soeiro MdeN, de Castro SL. Screening of Potential anti- Trypanosoma cruzi Candidates: In Vitro and In Vivo Studies. Open Med Chem J 2011; 5: 21-30.
15. Simarro PP, Jannin J, Cattand P. Eliminating human African trypanosomiasis: Where do we stand and what comes next? PLoS Med 2008; 5: e55
16. Jacobs RT, Nare B, Phillips MA State of the art in African trypanosome drug discovery. Curr Top Med Chem. 2011; 11: 1255-1274.
17. Gething MJ, Sambrook J. Protein folding in the cell. Nature 1992; 355: 33-45.
18. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med 2003; 228: 111-133.
19. Echeverria PC, Picard D. Molecular chaperones, essential partners of steroid hormone receptors for activity and mobility. Biochim Biophys Acta 2010; 1803: 641-649.
20. Johnson JL. Evolution and function of diverse Hsp90 homologs and cochaperone proteins. Biochim Biophys Acta 2012; 1823: 607-613.
21. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997; 89: 239-250.
22. Mimnaugh EG, Chavany C, Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor proteintyrosine kinase induced by geldanamycin. J Biol Chem 1996; 271: 22796-22801.
23. Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers Biochim Biophys Acta 2012; 1823: 742-755.
24. Banumathy G, Singh V, Pavithra SR, Tatu U. Heat shock protein 90 function is essential for Plasmodium falciparum growth in human erythrocytes. J Biol Chem 2003; 278: 18336-18345.
25. Graefe S, Wiesgigl M, Gaworski I, Macdonald A, Clos J. Inhibition of HSP90 in Trypanosoma cruzi induces a stress response but no stage differentiation. Eukaryot Cell 2002; 1: 936-943.
26. Echeverria PC, Matrajt M, Harb OS, Zappia MP, Costas MA, Roos DS, Dubremetz JF, Angel SO. Toxoplasma gondii Hsp90 is a potential drug target whose expression and subcellular localization are developmentally regulated. J Mol Biol 2005; 350: 723-734.
27. Wiesgigl M, Clos J. Heat Shock Protein 90 Homeostasis Controls Stage Differentiation in Leishmania donovani. Mol Biol Cell 2001; 12: 3307-3316.
28. Echeverria PC, Figueras MJ, Vogler M, Kriehuber T, de Miguel N, Deng B, Dalmasso MC, Matthews DE, Matrajt M, Haslbeck M, Buchner J, Angel SO. The Hsp90 co-chaperone p23 of Toxoplasma gondii: Identification, functional analysis and dynamic interactome determination. Mol Biochem Parasitol 2010; 172:129-140.
29. Pavithra SR, Kumar R, Tatu U. Systems analysis of chaperone networks in the malarial parasite Plasmodium falciparum. PLoS Comput Biol 2007; 3: 1701-1715.
30. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994; 91: 8324-8328.
31. DeBoer C, Meulman PA, Wnuk RJ, PetersonDH. Geldanamycin, a new antibiotic. J Antibiot 1970; 23: 442-447.
32. Whitesell L, Neckers L, Trepel J, Myers C. Tumoricidal activity of benzoquinonoid ansamycins against prostate cancer and primitive neural malignancies. WO9408578 (1994)
33. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Identification and structural characterization of the ATP/ADPbinding site in the Hsp90 molecular chaperone. Cell 1997; 90: 65-75.
34. Pearl LH, Prodromou C, Workman P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J. 2008; 410: 439-453.
35. Gomez-Monterrey I, Sala M, Musella S, Campiglia P. Heat shock protein 90 inhibitors as therapeutic agents. Recent Pat Anticancer Drug Discov 2012; 7:313-336.
36. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DTdiaphorase expression and tumor cell sensitivity to 17-allyamino- 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl Cancer Inst 1999; 91: 1940-1949.
37. Sydor J, Normant E, Pien C, Porter J, Ge J, Grenier L, Pak R, Ali J, Dembski M, Hudak J, Patterson J, Penders C, Pink M, Read M, Sang J, Woodward C, Zhang Y, Grayzel D, Wright J, Barrett J, Palombella V, Adams J, Tong J. Development of 17-allylamino- 17-demethoxygeldanamycin hydroquinone hydrochloride (IPI- 1152 504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci 2006; 103; 17408-17413.
38. Cowen LE, Carpenter AE, Matangkasombut O, Fink GR, Lindquist S. Genetic architecture of Hsp90-dependent drug resistance. Eukaryot Cell 2006; 5:2184-2188.
39. Cowen LE, Singh SD, Köhler JR, Collins C, Zaas AK, Schell WA, Aziz H, Mylonakis E, Perfect JR, Whitesell L, Lindquist S. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci USA 2009; 106:2818-2823.
40. Singh SD, Robbins N, Zaas AK, Schell WA, Perfect JR, Cowen LE. Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin. PLoS Pathog 2009; 5:e1000532.
41. Pachl J, Svoboda P, Jacobs F, Vandewoude K, van der Hoven B, Spronk P, Masterson G, Malbrain M, Aoun M, Garbino J, Takala J, Drgona L, Burnie J, Matthews R; Mycograb Invasive Candidiasis Study Group. A randomized, blinded, multicenter trial of lipidassociated amphotericin B alone versus in combination with an antibody- based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006; 42:1404-1413.
42. Pallavi R, Roy N, Nageshan RK, Talukdar P, Pavithra SR, Reddy R, Venketesh S, Kumar R, Gupta AK, Singh RK, Yadav SC, Tatu U. Heat shock protein 90 as a drug target against protozoan infections: biochemical characterization of HSP90 from Plasmodium falciparum and Trypanosoma evansi and evaluation of its inhibitor as a candidate drug. J Biol Chem 2010; 285: 37964-37975.
43. Hunter KW, Cook CL, Hayunga EG. Leishmanial differentiation in vitro: induction of heat shock proteins. Biochem Biophys Res Commun 1984;125:755-760.
44. Argaman M, Aly R, Shapira M. Expression of heat shock protein 83 in Leishmania is regulated post-transcriptionally. Mol Biochem Parasitol 1994; 64:95-110.
45. Brandau S, Dresel A, Clos J. High constitutive levels of heat-shock proteins in human-pathogenic parasites of the genus Leishmania. Biochem J 1995; 310:225-232.
46. Li Q, Zhou Y, Yao C, Ma X, Wang L, Xu W, Wang Z, Qiao Z. Apoptosis caused by Hsp90 inhibitor geldanamycin in Leishmania donovani during promastigote-to-amastigote transformation stage. Parasitol Res 2009; 105: 1539-1548.
47. Shahinas D, Liang M, Datti A, Pillai DR. A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90. J Med Chem 2010; 53:3552-3557.
48. Ahn HJ, Kim S, Nam HW. Molecular cloning of the 82-kDa heat shock protein (HSP90) of Toxoplasma gondii associated with the entry into and growth in host cells. Biochem Biophys Res Commun 2003; 311: 654-659.
49. Mout R, Xu ZD, Wolf AK, Davisson VJ, Jarori GK. Anti-malarial activity of geldanamycin derivatives in mice infected with Plasmodium yoelii. Malar J 2012; 11: 54.
50. Matrajt, M. L.; Angel, S. O.; Echeverria, P. C.: US20117968096 (2011).
51. Tatu, U.; Pavithra, R. S.; Banumathy, G.: US20097611853 (2009).
52. Wenkert, D., Kuhn, L., Scheller, E., Kron, M., Shen, Y.: WO2007098229 (2007).